BIO/Food Value Chain letter to Senate and House Appropriations Committee leadership in support of legislative language ensuring consistency under the National Bioengineered Food Disclosure Law
September 27, 2018
September 21, 2018
The Honorable Richard Shelby The Honorable Patrick Leahy Chairman Vice Chairman Committee on Appropriations Committee on Appropriations U.S. Senate U.S. Senate Washington, D.C. 20510 Washington, D.C. 20510
The Honorable Rodney Frelinghuysen The Honorable Nita Lowey Chairman Ranking Member Committee on Appropriations Committee on Appropriations U.S. House of Representatives U.S. House of Representatives Washington, D.C. 20515 Washington, D.C. 20515
Dear Chairman Shelby, Chairman Frelinghuysen, Vice Chairman Leahy, and Ranking Member Lowey:
As representatives of the U.S. food value chain, we write to express our support for Section 766 of H.R. 5961, the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY 2019, pertaining to product disclosure consistency under the National Bioengineered Food Disclosure Law (the “Disclosure Act”, or “the Act”). This provision will ensure that all bioengineered foods are properly disclosed to consumers consistent with the Disclosure Act, helping to prevent consumer confusion and increasing the Act’s value to consumers. Similarly, we oppose a conflicting provision in the Senate passed version of this legislation that would increase consumer confusion and undermine the intent of the Act...
Download Full Comments Below
Food Value Chain Letter On Appropriations Disclosure Consistency Language-9-21-18
On behalf of its member organizations, Biotechnology Innovation Organization (“BIO”) respectfully submits this Comment in response to the United States Patent and Trademark Office’s (the “Patent Office” or “PTO”) February 13, 2024 Request for…
BIO submits comments on the MDH’s proposed regulations regarding Drugs of Substantial Public Interest: Draft Methodology for Public Comment as required in statute by the Prescription Drug Price Transparency Act.
September 21, 2018
The Honorable Richard Shelby The Honorable Patrick Leahy
Chairman Vice Chairman
Committee on Appropriations Committee on Appropriations
U.S. Senate U.S. Senate
Washington, D.C. 20510 Washington, D.C. 20510
The Honorable Rodney Frelinghuysen The Honorable Nita Lowey
Chairman Ranking Member
Committee on Appropriations Committee on Appropriations
U.S. House of Representatives U.S. House of Representatives
Washington, D.C. 20515 Washington, D.C. 20515
Dear Chairman Shelby, Chairman Frelinghuysen, Vice Chairman Leahy, and Ranking Member Lowey:
As representatives of the U.S. food value chain, we write to express our support for Section 766 of H.R. 5961, the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY 2019, pertaining to product disclosure consistency under the National Bioengineered Food Disclosure Law (the “Disclosure Act”, or “the Act”). This provision will ensure that all bioengineered foods are properly disclosed to consumers consistent with the Disclosure Act, helping to prevent consumer confusion and increasing the Act’s value to consumers. Similarly, we oppose a conflicting provision in the Senate passed version of this legislation that would increase consumer confusion and undermine the intent of the Act...